Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs

被引:82
作者
Gardiner, Sharon J.
Gearry, Richard B.
Roberts, Rebecca L.
Zhang, Mei
Barclay, Murray L.
Begg, Evan J.
机构
[1] Christchurch Sch Med, Dept Med, Christchurch, New Zealand
[2] Christchurch Hosp, Dept Med, Christchurch, New Zealand
[3] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand
[4] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand
[5] Christchurch Hosp, Dept Pathol, Christchurch, New Zealand
关键词
azathioprine; breastfeeding; pharmacogenetics; pharmacokinetics;
D O I
10.1111/j.1365-2125.2006.02639.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To determine infant exposure to 6-thioguanine and 6-methylmercaptopurine nucleotides (6-TGN and 6-MMPN, respectively) during maternal use of azathioprine in breastfeeding. Methods Mother-infant pairs provided blood for determination of 6-TGN and 6-MMPN concentrations, and TPMT genotype. Results Four women taking azathioprine 1.2-2.1 mg kg(-1) day(-1) and their infants were studied. All had the wild-type TPMT genotype. Maternal 6-TGN and 6-MMPN concentrations ranged from 234 to 291 and 284 to 1178 pmol per 8 x 10(8) red blood cells, respectively, and were consistent with those associated with improved therapeutic outcomes. Neither 6-TGN nor 6-MMPN was detected in any of the infants, despite a sensitive assay. Conclusions The data suggest that azathioprine may be 'safe' during breastfeeding in patients with the wild-type TPMT genotype (similar to 90% of caucasian patients) taking 'normal' doses.
引用
收藏
页码:453 / 456
页数:4
相关论文
共 19 条
[1]  
[Anonymous], 2001, OPTIMAL DURATION EXC
[2]   Drug safety issues in pregnancy following transplantation and immunosuppression - Effects and outcomes [J].
Armenti, VT ;
Moritz, MJ ;
Davison, JM .
DRUG SAFETY, 1998, 19 (03) :219-232
[3]  
Begg Evan J, 2002, J Hum Lact, V18, P323, DOI 10.1177/089033402237904
[4]  
Bennett PN., 1996, DRUGS HUMAN LACTATIO
[5]   A SIMPLE METHOD FOR DNA PURIFICATION FROM PERIPHERAL-BLOOD [J].
CIULLA, TA ;
SKLAR, RM ;
HAUSER, SL .
ANALYTICAL BIOCHEMISTRY, 1988, 174 (02) :485-488
[6]  
COULAM CB, 1982, TRANSPLANT P, V14, P605
[7]   Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease - Implications for therapy [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
Curvers, WL ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2004, 26 (03) :311-318
[8]   Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease [J].
Dubinsky, MC ;
Lamothe, S ;
Yang, HY ;
Targan, SR ;
Sinnett, D ;
Théorêt, Y ;
Seidman, EG .
GASTROENTEROLOGY, 2000, 118 (04) :705-713
[9]   Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice [J].
Gearry, RB ;
Barclay, ML ;
Roberts, RL ;
Harraway, J ;
Zhang, M ;
Pike, LS ;
George, PM ;
Florkowski, CM .
INTERNAL MEDICINE JOURNAL, 2005, 35 (10) :580-585
[10]   IMMUNOSUPPRESSIVE THERAPY AND BREAST-FEEDING AFTER RENAL-TRANSPLANTATION [J].
GREKAS, DM ;
VASILIOU, SS ;
LAZARIDES, AN .
NEPHRON, 1984, 37 (01) :68-68